Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net

Blood (2024) 144 (Supplement 1): 6063.

https://doi.org/10.1182/blood-2024-200013

Published: 2024

Journal Articles

Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study

Blood (2023) 142 (Supplement 1): 1470.

https://doi.org/10.1182/blood-2023-173909

Published: 2023

Journal Articles

Detailed Assessment of Blood Culture and Clinical Factors in Febrile Neutropenia Patients with High-Risk Hematological Malignancy in Japan: A Subgroup Analysis of the Cedmic Trial

Akinao Okamoto, Yoshinobu Kanda, MD PhD, Shun-Ichi Kimura, MD, Tatsuo Oyake, MD PhD, Kazuo Tamura, MD PhD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-134117

Published: 2020

Journal Articles

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Tatsuo Oyake, Norifumi Sugawara, MD, PhD, Shinri Miyajima, MD, Kazuki Kiyohara, MD, Maki Nishiya, MD PhD, Tadashi Shimoyama, MD PhD, Yuka Takemasa-Fujisawa, MD PhD, Ryosei Sasaki, MD PhD, Wataru Izumita, MD, Yasuhiko Tsukushi, MD, PhD, Akihiro Otsu, MD, PhD, Takahiro Mine, MD, Takeshi Sugawara, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, PhD, Ichiro Hanamura, MD PhD, Shugo Kowata, MD, PhD, Shigeki Ito, MD, PhD

Blood (2019) 134 (Supplement_1): 4865.

https://doi.org/10.1182/blood-2019-131305

Published: 2019

Journal Articles

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Daigo Michimata, MD, Kazunori Murai, MD PhD, Yasuro Miyairi, MD, PhD, Yoshiaki Okano, MD, PhD, Yuuzou Suzuki, MD, PhD, Hiroyuki Hamada, MD, Akiyoshi Sato, MD, PhD, Tatsuo Oyake, Shugo Kowata, MD, PhD, Yasuhiko Tsukushi, MD, PhD, Norifumi Sugawara, MD, PhD, Akihiro Otsu, MD, PhD, Kenji Shimosegawa, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2019) 134 (Supplement_1): 2928.

https://doi.org/10.1182/blood-2019-125066

Published: 2019

Journal Articles

Classical Empiric Antifungal Therapy Vs. D-Index Guided Early Therapy Using Micafungin for Persistent Febrile Neutropenia (CEDMIC trial): A Randomized Controlled Trial from Japan FN Study Group

Shun-Ichi Kimura, MD PhD, Yoshinobu Kanda, MD PhD, Masaki Iino, MD PhD, Takahiro Fukuda, MD PhD, Emiko Sakaida, MD PhD, Tatsuo Oyake, Hiroki Yamaguchi, MD PhD, Shin-ichiro Fujiwara, MD PhD, Junji Suzumiya, MD PhD, Akinao Okamoto, MD PhD, Hiroyuki Fujita, MD PhD, Yasushi Takamatsu, MD PhD, Yoshio Saburi, MD PhD, Jun Yamanouchi, MD PhD, Itaru Matsumura, MD, Souichi Shiratori, Moritaka Gotoh, MD PhD, Shingen Nakamura, MD PhD, Kazuo Tamura, MD PhD

Blood (2018) 132 (Supplement 1): 816.

https://doi.org/10.1182/blood-2018-99-111154

Published: 2018

Journal Articles

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Ryousei Sasaki, MD, PhD, Wataru Izumita, MD, Takahiro Mine, MD, Maki Asahi, MD, PhD, Yuzo Suzuki, MD, PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yasuhiko Tsukushi, MD, PhD, Yusei Aoki, MD, Shugo Kowata, MD, PhD, Ichiro Hanamura, MD, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2016) 128 (22): 1607.

https://doi.org/10.1182/blood.V128.22.1607.1607

Published: 2016

Journal Articles

First-Line Dasatinib Treatment of CML-CP Leads to Earlier Achievement of MMR and MR4.5 with High Safety

Blood (2016) 128 (22): 3102.

https://doi.org/10.1182/blood.V128.22.3102.3102

Published: 2016

Journal Articles

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Tatsuo Oyake, MD PhD, Takayuki Masuda, MD PhD, Norifumi Sugawara, MD PhD, Maki Asahi, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD PhD, Shigeki Ito, MD PhD, Yoji Ishida, MDPhD

Blood (2015) 126 (23): 4621.

https://doi.org/10.1182/blood.V126.23.4621.4621

Published: 2015

Journal Articles

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Yasunori Nakagawa, MD, PhD, Takahiro Mine, MD, Ichiro Hanamura, MD, PhD, Maki Asahi, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4954.

https://doi.org/10.1182/blood.V124.21.4954.4954

Published: 2014

Journal Articles

Index to Predict MMR at 12 Months in Chronic Phase Chronic Myeloid Leukemia Patients Based on the Area Under the Lymphocyte Curve

Kazunori Murai, PhD MD, Shigeki Ito, MD PhD, Shugo Kowata, MD, Tatsuo Oyake, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4560.

https://doi.org/10.1182/blood.V124.21.4560.4560

Published: 2014

Journal Articles

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Tadashi Shimoyama, MD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 1456.

https://doi.org/10.1182/blood.V124.21.1456.1456

Published: 2014

Journal Articles

Doripenem Versus Meropenem For Empirical Antimicrobial Therapy In High Risk Febrile Neutropenic Patients With Hematological Malignancies: A Randomized, Controlled Trial

Yuka Fujisawa, M.D., Tatsuo Oyake, M.D., Ph.D., Takahiro Mine, M.D., Yusei Aoki, M.D., Yasuhiko Tsukushi, M.D., Ph.D., Takeshi Sugawara, M.D., Masato Seguchi, M.D., Ph.D., Ichiro Hanamura, M.D., Ph.D., Yasuaki Nakagawa, M.D., Ph.D., Kazunori Murai, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 4716.

https://doi.org/10.1182/blood.V122.21.4716.4716

Published: 2013

Journal Articles

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Shigeki Ito, M.D., Ph.D., Maki Asahi, MD, Ryousei Sasaki, MD, Tatsuo Oyake, M.D., Ph.D., Hideto Tamura, MD, PhD, Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1667.

https://doi.org/10.1182/blood.V122.21.1667.1667

Published: 2013

Journal Articles

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Yukiteru Fujishima, MD, Yasuhiko Tsukushi, M.D., Takahiro Mine, MD., Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1071.

https://doi.org/10.1182/blood.V122.21.1071.1071

Published: 2013

Journal Articles

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Tatsuo Oyake, M.D., Ph.D., Tadashi Shimoyama, Maki Asahi, Sugawara Norifumi, Ryosei Sasaki, Suzuki Yuzo, Fujishima Yukiteru, Yasuhiko Tsukushi, M.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2012) 120 (21): 2186.

https://doi.org/10.1182/blood.V120.21.2186.2186

Published: 2012

Journal Articles

Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes

Kazunori Murai, MD, PhD, Shugo Kowata, MD, Akiko Abo, MD, PhD, Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2011) 118 (21): 2228.

https://doi.org/10.1182/blood.V118.21.2228.2228

Published: 2011

Journal Articles

Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.

Kazunori Murai, MD, PhD, Shugo Kowata, MD, Akiko Abo, MD, PhD, Tatsuo Oyake, MD, PhD, Kenichi Nomura, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 3696.

https://doi.org/10.1182/blood.V116.21.3696.3696

Published: 2010

Journal Articles

Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial.

Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Tomoaki Akagi, MD, PhD, Koumei Kubo, MD, PhD, Kenichi Sawada, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 1062.

https://doi.org/10.1182/blood.V116.21.1062.1062

Published: 2010

Journal Articles

Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production

Shugo Kowata, MD, Kazunori Murai, MD, PhD, Kenichi Nomura, MD, PhD, Tatsuo Oyake, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 4793.

https://doi.org/10.1182/blood.V116.21.4793.4793

Published: 2010

NARROW

Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net

Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study

Detailed Assessment of Blood Culture and Clinical Factors in Febrile Neutropenia Patients with High-Risk Hematological Malignancy in Japan: A Subgroup Analysis of the Cedmic Trial

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Classical Empiric Antifungal Therapy Vs. D-Index Guided Early Therapy Using Micafungin for Persistent Febrile Neutropenia (CEDMIC trial): A Randomized Controlled Trial from Japan FN Study Group

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

First-Line Dasatinib Treatment of CML-CP Leads to Earlier Achievement of MMR and MR4.5 with High Safety

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Index to Predict MMR at 12 Months in Chronic Phase Chronic Myeloid Leukemia Patients Based on the Area Under the Lymphocyte Curve

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Doripenem Versus Meropenem For Empirical Antimicrobial Therapy In High Risk Febrile Neutropenic Patients With Hematological Malignancies: A Randomized, Controlled Trial

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes

Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.

Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial.

Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only